(24/7 MARKET NEWS) – Spruce Biosciences, Inc. (Nasdaq: SPRB) and Kaken Pharmaceutical Co. Ltd (Tokyo Stock Exchange: 4521) announced, after yesterday’s market close, that the companies entered into an exclusive licensing agreement for the development and commercialization of Spruce’s product candidate, tildacerfont, for the treatment of congenial adrenal hyperplasia (CAH) in Japan. Spruce will receive a $15 million upfront payment plus development and commercial milestone payments, in addition to tiered double-digit royalties on net sales in Japan.
It’s trading higher this morning, at $2.19, up $0.94 (+75.20%), on volume of 2.5 million shares.
Its 52-week range is $0.9547 to $4.18. If it can trade above $2.40, on strong volume, it’s setup is favorable for a potential run to much higher levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.